• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2018 May;7(2):123-133. doi: 10.1159/000488542. Epub 2018 Apr 17.

DOI:10.1159/000488542
PMID:29888203
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5985409/
Abstract
摘要

相似文献

1
Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.卡博替尼作为晚期肝细胞癌的二线治疗药物
Liver Cancer. 2018 May;7(2):123-133. doi: 10.1159/000488542. Epub 2018 Apr 17.
2
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.卡博替尼二线治疗晚期肝细胞癌的成本效益分析。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):669-675. doi: 10.6004/jnccn.2018.7275.
3
Cabozantinib for the treatment of hepatocellular carcinoma.卡博替尼治疗肝细胞癌。
Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11.
4
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma.综述：卡博替尼治疗晚期肾细胞癌和肝细胞癌
Cancer Manag Res. 2020 May 20;12:3741-3749. doi: 10.2147/CMAR.S202973. eCollection 2020.
5
Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma酪氨酸激酶抑制剂在肝细胞癌治疗中的应用
6
Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.卡博替尼用于既往接受血管内皮生长因子靶向治疗的成年晚期肾细胞癌患者的治疗：临床试验证据与经验
Ther Adv Urol. 2018 Jan 9;10(3):109-123. doi: 10.1177/1756287217748867. eCollection 2018 Mar.
7
Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.卡博替尼治疗晚期肝细胞癌的疗效和安全性的暴露-反应分析。
J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):577-589. doi: 10.1007/s10928-019-09659-y. Epub 2019 Oct 21.
8
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.卡博替尼：晚期肝细胞癌的研究进展。
Target Oncol. 2019 Feb;14(1):107-113. doi: 10.1007/s11523-019-00622-y.
9
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use.卡博替尼作为晚期肾细胞癌的一线治疗：其应用概述
Drugs Ther Perspect. 2018;34(10):457-465. doi: 10.1007/s40267-018-0547-6. Epub 2018 Aug 7.
10
Cabozantinib in the treatment of hepatocellular carcinoma.卡博替尼治疗肝细胞癌
Future Oncol. 2017 Sep;13(22):1915-1929. doi: 10.2217/fon-2017-0169. Epub 2017 Jul 13.

引用本文的文献

1
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.卡博替尼通过抑制肝星状细胞和巨噬细胞的激活以及减弱血管生成活性来预防代谢功能障碍相关脂肪性肝炎的进展。
Heliyon. 2024 Sep 27;10(19):e38647. doi: 10.1016/j.heliyon.2024.e38647. eCollection 2024 Oct 15.
2
Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering.靶向医学与生物工程时代的肝细胞癌个性化治疗
Front Pharmacol. 2023 May 5;14:1150151. doi: 10.3389/fphar.2023.1150151. eCollection 2023.
3
Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials.改善酪氨酸激酶抑制剂在肝细胞癌中的疗效：新数据与正在进行的试验
Front Oncol. 2021 Oct 11;11:752725. doi: 10.3389/fonc.2021.752725. eCollection 2021.
4
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.卡博替尼治疗晚期肝细胞癌：来自国际多中心真实世界队列的疗效和安全性数据
Liver Cancer. 2021 Jul;10(4):360-369. doi: 10.1159/000515490. Epub 2021 Jun 1.
5
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.成纤维细胞生长因子 19/成纤维细胞生长因子受体 4 信号抑制对多激酶抑制剂在肝细胞癌中抗肿瘤活性的影响。
Sci Rep. 2021 Mar 5;11(1):5303. doi: 10.1038/s41598-021-84117-9.
6
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.老龄化社会中肝细胞癌全身治疗的最新进展：2020年更新
Liver Cancer. 2020 Dec;9(6):640-662. doi: 10.1159/000511001. Epub 2020 Nov 17.
7
Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma.雷莫西尤单抗在日本不可切除肝细胞癌患者中的疗效优于全球总体人群。
Liver Cancer. 2020 Jun;9(3):232-244. doi: 10.1159/000507889. Epub 2020 May 29.
8
LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway.长链非编码RNA HEIH通过调控miR-98-5p/PI3K/AKT通路赋予肝癌细胞对索拉非尼的抗性。
Cancer Manag Res. 2020 Jul 29;12:6585-6595. doi: 10.2147/CMAR.S241383. eCollection 2020.
9
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis.卡博替尼用于晚期肝细胞癌患者：一项成本效益分析。
Therap Adv Gastroenterol. 2019 Sep 23;12:1756284819878304. doi: 10.1177/1756284819878304. eCollection 2019.
10
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.针对肝细胞癌的靶向和免疫治疗：2019 年及以后的预测。
World J Gastroenterol. 2019 Feb 21;25(7):789-807. doi: 10.3748/wjg.v25.i7.789.

本文引用的文献

1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
2
Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.晚期肝细胞癌全身治疗的疗效与安全性：一项III期试验的网状Meta分析
Liver Cancer. 2017 Nov;6(4):337-348. doi: 10.1159/000481314. Epub 2017 Oct 19.
3
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.瑞戈非尼和乐伐替尼开启肝细胞癌系统治疗新时代。
Liver Cancer. 2017 Jun;6(3):177-184. doi: 10.1159/000462153. Epub 2017 Mar 9.
4
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.索拉非尼耐药的晚期肝细胞癌患者中 S-1 与安慰剂的比较（S-CUBE）：一项随机、双盲、多中心、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417. doi: 10.1016/S2468-1253(17)30072-9. Epub 2017 Apr 6.
5
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.卡博替尼治疗肝细胞癌：一项2期安慰剂对照随机停药研究的结果
Ann Oncol. 2017 Mar 1;28(3):528-534. doi: 10.1093/annonc/mdw651.
6
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌的分子靶向药物：现状与未来展望
Liver Cancer. 2017 Feb;6(2):101-112. doi: 10.1159/000452138. Epub 2016 Dec 15.
7
Giving AXL the axe: targeting AXL in human malignancy.淘汰AXL：在人类恶性肿瘤中靶向作用于AXL
Br J Cancer. 2017 Feb 14;116(4):415-423. doi: 10.1038/bjc.2016.428. Epub 2017 Jan 10.
8
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
9
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.瑞戈非尼作为二线全身治疗可能会改变肝细胞癌的治疗策略和管理模式。
Liver Cancer. 2016 Oct;5(4):235-244. doi: 10.1159/000449335. Epub 2016 Sep 14.
10
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.雷莫芦单抗二线治疗索拉非尼一线治疗后晚期肝细胞癌患者（REACH）：一项随机、双盲、多中心、III 期临床试验。
Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.